Scilex Holding Company (SCLX)
Nasdaq · Healthcare · Drug Manufacturers - General
$3.82−5.91%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $26.9M
- Forward P/E
- 5.2
- 52-week range
- $2.62 – $16.81
- 52-week change
- −64.23%
- EPS (trailing)
- −$49.70
Fiscal year to Dec 2025
- Revenue
- $30.3M (−46.54%)
- Net income
- −$374M
- Operating margin
- −1143.7%
- Diluted EPS
- −$36.48
- Free cash flow
- $3.7M
From the company’s annual report on SEC EDGAR.
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Headquarters: Palo Alto, United States · 34 employees · scilexholding.com